Analysis Of The Weekly Performance Of Legend Biotech Corporation (LEGN)

Legend Biotech Corporation (NASDAQ:LEGN) finished Friday with a subtraction of -$0.47 to close at $53.08, a downside of -0.88 percent. An average of 349,900 shares of common stock have been traded in the last five days. There was a gain of $1.17 in the past week, and it reached a new high 25 times over the past 12 months. The last 20 days have seen an average of 472,815 shares traded, while the 50-day average volume stands at 408,376.

LEGN stock has increased by 11.63% in the last month. The company shares reached their 1-month lowest point of $45.23 on 09/27/21. With the stock rallying to its 52-week high on 10/12/21, shares of the company touched a low of $23.41 and a high of $58.00 in 52 weeks. It has reached a new high 24 times so far this year and achieved 88.49% or $24.92 in price. In spite of this, the price is down -8.48% from the 52-week high.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Valuation Metrics

Legend Biotech Corporation (LEGN) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.43 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 88.58, the price-to-book (PB) ratio at 21.67.

The quick ratio of Legend Biotech Corporation for the three months ended June 29 was 2.80, and the current ratio was 2.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.06 and a total debt to equity ratio of 0.06 for the quarter ending June 29. Legend Biotech Corporation’s EBITDA margin for the year ending June 29 is -289.75%. Its gross profit as reported stood at $305.22 million compared to revenue of $81.8 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Legend Biotech Corporation’s return on assets was -40.70%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

For the three-month period that ended June 29, Legend Biotech Corporation had $0.55 million in total debt. The analyst consensus anticipated Legend Biotech Corporation’s latest quarter earnings to come in at -$0.34 per share, but it turned out to be -$0.33, a 2.90% surprise. For the quarter, EBITDA amounted to -$89.93 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Legend Biotech Corporation (LEGN) price momentum. RSI 9-day as of the close on 22 October was 55.86%, suggesting the stock is Neutral, with historical volatility in this time frame at 56.97%.

As of today, LEGN’s price is $53.44 +2.25% or $1.17 from its 5-day moving average. LEGN is currently trading +12.46% higher than its 20-day SMA and +31.94% higher than its 100-day SMA. However, the stock’s current price level is +32.34% above the SMA50 and +83.92% above the SMA200.

The stochastic %K and %D were 51.98% and 57.14%, respectively, and the average true range (ATR) was 2.89. With the 14-day stochastic at 44.66% and the average true range at 2.81, the RSI (14) stands at 59.46%. The stock has reached 0.39 on the 9-day MACD Oscillator while the 14-day reading was at 0.17.

Analyst Ratings

BTIG Research launched coverage on Legend Biotech Corporation (NASDAQ: LEGN) in its analyst report released on May 18, 2021. The firm assigned the stock a a Buy rating. The consensus rating for Legend Biotech Corporation (LEGN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell LEGN, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.

What is LEGN’s price target for the next 12 months?

Analysts predict a range of price targets between $50.00 and $70.00, with a median target of $56.00. Taking a look at these predictions, the average price target given by analysts for Legend Biotech Corporation (LEGN) stock is $58.40.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam